CORT
Corcept Therapeutics Incorporated
NASDAQ: CORT · HEALTHCARE · BIOTECHNOLOGY
$112.79
-1.85% today
Updated 2026-09-11
Market cap
$12.32B
P/E ratio
253.29
P/S ratio
14.83x
EPS (TTM)
$0.45
Dividend yield
—
52W range
$29 – $126
Volume
1.1M
WallStSmart proprietary scores
60
out of 100
Grade: C+
Hold
Investment rating
9.3
Growth
A+8.0
Quality
A5.0
Profitability
C+5.0
Valuation
C+2/9
Piotroski F-Score
Weak
4.8
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$70.83
-37.20%
12-Month target
$24.55
-78.23%
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy2 Buy0 Hold1 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 4.77 — safe zone
+ Free cash flow $31.02M — positive
+ Revenue growth 31.70% QoQ
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- P/E 253.29x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $401.86M | $482.38M | $675.04M | $761.41M | $830.81M | $1.0B |
| Net income | $101.42M | $106.14M | $139.73M | $99.65M | $42.14M | — |
| EPS | — | — | — | — | $0.45 | $0.68 |
| Free cash flow | $119.91M | $126.90M | $195.90M | $141.78M | $31.02M | — |
| Profit margin | 25.24% | 22.00% | 20.70% | 13.09% | 6.64% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-09-02 | VIEIRA, ROBERTO WANDENKOLK | Sale | 58,333 | — |
| 2026-09-02 | VIEIRA, ROBERTO WANDENKOLK | Buy | 58,333 | $21.63 |
| 2026-09-02 | VIEIRA, ROBERTO WANDENKOLK | Sale | 23,770 | $110.70 |
Peer comparison
Smart narrative
Corcept Therapeutics Incorporated trades at $112.79. representing a P/E of 253.29x trailing earnings. Our Smart Value Score of 60/100 indicates the stock is good. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 4.77, it sits in the safe zone. TTM revenue stands at $830.81M. with profit margins at 6.64%.
Frequently asked questions
What is Corcept Therapeutics Incorporated's stock price?
Corcept Therapeutics Incorporated (CORT) trades at $112.79, on a P/E of 253.3x and a P/S of 14.8x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Corcept Therapeutics Incorporated overvalued?
Corcept Therapeutics Incorporated carries a Smart Value Score of 60/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of Corcept Therapeutics Incorporated (CORT)?
The 12-month analyst consensus target is $70.83, about 37.2% below the current $112.79. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of CORT by 2030?
Our research-backed model puts the 2030 base case at $76.50, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is Corcept Therapeutics Incorporated's revenue?
Corcept Therapeutics Incorporated's trailing twelve-month revenue is $830.81M, and our model projects it reaching about $1.78B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Corcept Therapeutics Incorporated's Altman Z-Score is 4.77, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio14.83x
ROE7.78%
Beta0.45
50D MA$104.08
200D MA$66.81
Shares out0.11B
Float0.10B
Short ratio—
Avg volume1.1M
Performance
1 week+1.05%
1 month-1.47%
3 months+36.04%
YTD+224.11%
1 year+54.78%
3 years—
5 years—